Selected Publications:


Selected Posters and Presentations:


**Steatohepatitis (NASH) and Circulating Markers of Apoptosis and Cell Injury**
Annual Meeting of the American Association for the Study of Liver Disease (2016) Submitted


4. Spencer Frost, [J. Michael Estep](#), Kellie Perry, Sean Felix, Leo McLaughlin, Brian Lam, Maria Stepanova, Pegah Golabi, Lynn Gerber, Zobair M. Younossi. **Interferon lambda 4 (IFN-λ4) genotype is associated with fatigue in patients with chronic hepatitis C (CH-C) receiving direct-acting antiviral (DAA) treatment** Digestive Disease Week (2016)

5. Pegah Golabi, Mehmet Sayiner, [J. Michael Estep](#), Spencer Frost, Brian Lam, Sean Felix, Rose Srishord, Lynn Gerber, Zobair M. Younossi. **Association of Fatigue with Serum Tumor Necrosis Factor-α (TNF-α) and Chemokine (C-C motif) Ligand 2 (CCL2) in Patients with Chronic Hepatitis C Virus (HCV) Infection** Digestive Disease Week (2016)


7. Zobair M. Younossi, Maria Stepanova, [J. Michael Estep](#), Azza Karrar, Bibiana Oe, Elzafir Elsheikh, Siddharth Hariharan, Kazi Ahmed, Patricia Tran, Fatema Nader, Linda Henry, Ali A. Weinstein, Naomi Lynn Gerber. **TNF-alpha is the Most Consistent Predictor of Impairment of Mental Health-Related Patient-Reported Outcomes (PROs) in Patients with Chronic Hepatitis C (CH-C) Treated with Ledipasvir (LDV) and Sofosbuvir (SOF) with or without Ribavirin (RBV)** Annual Meeting of the American Association for the Study of Liver Disease (2015).

8. Pegah Golabi, Mehmet Sayiner, [J. Michael Estep](#), Elzafir Elsheikh, Brian P. Lam, Huong T. Pham, Maria Stepanova, Zobair M. Younossi. **Treatment of Hepatitis C Virus with Direct Acting Antivirals (DAA) and Ribavirin (RBV) is Associated with Changes in Serum Apolipoprotein and TNF-alpha Levels** Annual Meeting of the American Association for the Study of Liver Disease (2015).


10. Lynn Gerber, [J. Michael Estep](#), Elzafir Elsheikh, Maria Stepanova, Carey Escheik, Zobair M Younossi. **Improvement of Central and Peripheral Fatigue and Associated Biomarkers After Sustained Virologic Response (SVR) with Ledipasvir (LDV)/Sofosbuvir (SOF) in Patients with Chronic Hepatitis C Virus (CH-C)** Digestive Disease Week (2015)


(VAT) of Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Digestive Disease Week (2013).


Steatohepatitis (NASH) and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Annual Meeting of the European Association for the Study of Liver Diseases, Vienna, Austria (2011).


